WO2001005821A3 - Utilisations de l'il-10 virale - Google Patents

Utilisations de l'il-10 virale Download PDF

Info

Publication number
WO2001005821A3
WO2001005821A3 PCT/EP2000/006558 EP0006558W WO0105821A3 WO 2001005821 A3 WO2001005821 A3 WO 2001005821A3 EP 0006558 W EP0006558 W EP 0006558W WO 0105821 A3 WO0105821 A3 WO 0105821A3
Authority
WO
WIPO (PCT)
Prior art keywords
viral
metastasis
angiogenesis
tumorigenesis
inhibition
Prior art date
Application number
PCT/EP2000/006558
Other languages
English (en)
Other versions
WO2001005821A2 (fr
Inventor
Maria Teresa Bejarano
Original Assignee
Maria Teresa Bejarano
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maria Teresa Bejarano filed Critical Maria Teresa Bejarano
Priority to AU58270/00A priority Critical patent/AU5827000A/en
Publication of WO2001005821A2 publication Critical patent/WO2001005821A2/fr
Publication of WO2001005821A3 publication Critical patent/WO2001005821A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne divers procédés relatifs à l'utilisation de l'IL-10 virale, et en particulier le fait que l'IL-10 virale est capable d'inhiber l'angiogenèse, l'action tumorigène et la métastase.
PCT/EP2000/006558 1999-07-16 2000-07-11 Utilisations de l'il-10 virale WO2001005821A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU58270/00A AU5827000A (en) 1999-07-16 2000-07-11 Viral il-10 uses

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35483399A 1999-07-16 1999-07-16
US09/354,833 1999-07-16
US16362799P 1999-11-04 1999-11-04
US60/163,627 1999-11-04

Publications (2)

Publication Number Publication Date
WO2001005821A2 WO2001005821A2 (fr) 2001-01-25
WO2001005821A3 true WO2001005821A3 (fr) 2001-07-19

Family

ID=26859813

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/006558 WO2001005821A2 (fr) 1999-07-16 2000-07-11 Utilisations de l'il-10 virale

Country Status (2)

Country Link
AU (1) AU5827000A (fr)
WO (1) WO2001005821A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026265A2 (fr) 2000-09-29 2002-04-04 Schering Corporation Interleukine 10 pegylee
WO2002066069A1 (fr) * 2001-02-20 2002-08-29 Kansai Technology Licensing Organization Co., Ltd. Remedes contre l'inflammation/les maladies tumorales
AU2007314501B2 (en) 2006-09-28 2013-05-23 Merck Sharp & Dohme Corp. Use of pegylated IL-10 to treat cancer
RU2549702C2 (ru) 2008-12-17 2015-04-27 Мерк Шарп И Доум Корп., Получение и применение моно- и ди-пэг il-10
CN106913865A (zh) 2013-04-18 2017-07-04 阿尔莫生物科技股份有限公司 使用白细胞介素‑10治疗疾病和病症的方法
EP3010527B1 (fr) 2013-06-17 2018-08-08 Armo Biosciences, Inc. Méthode d'évaluation de l'identité et de la stabilité d'une protéine
CN105658232A (zh) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
RU2016122957A (ru) 2013-11-11 2017-12-19 Армо Байосайенсиз, Инк. Способы применения интерлейкина-10 для лечения заболеваний и расстройств
WO2015187295A2 (fr) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Méthodes permettant de faire baisser le cholestérol sérique
AU2015333827A1 (en) 2014-10-14 2017-04-20 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
KR20170084033A (ko) 2014-10-22 2017-07-19 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위해 인터루킨-10을 사용하는 방법
WO2016126615A1 (fr) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Procédés d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles
WO2016191587A1 (fr) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Interleukine 10 pégylée utilisée pour le traitement du cancer
WO2017035232A1 (fr) 2015-08-25 2017-03-02 Armo Biosciences, Inc. Procédés d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012725A1 (fr) * 1991-01-16 1992-08-06 Schering Corporation Traitement de maladie neoplastique a l'interleukine 10
US5770190A (en) * 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012725A1 (fr) * 1991-01-16 1992-08-06 Schering Corporation Traitement de maladie neoplastique a l'interleukine 10
US5770190A (en) * 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BENJAMIN DAVID: "Interleukin-10 (IL-10)", CANCER TREATMENT RESEARCH, vol. 80, 1995, pages 305 - 319, XP000979179 *
BERMAN ROBERT M ET AL: "Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice.", JOURNAL OF IMMUNOLOGY, vol. 157, no. 1, 1996, pages 231 - 238, XP002158947, ISSN: 0022-1767 *
CERVENAK LASZLO ET AL: "Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by interleukin-10.", BLOOD, vol. 96, no. 7, 1 October 2000 (2000-10-01), pages 2568 - 2573, XP002159072, ISSN: 0006-4971 *
DE WAAL MALEFYT R ET AL: "THE BIOLOGY OF HUMAN AND VIRAL IL-10", CYTOKINE, vol. 3, no. 5, 1991, pages 500, XP002158949, ISSN: 1043-4666 *
HUANG SUYUN ET AL: "Interleukin 10 Suppresses Tumor Growth and Metastasis of Human Melanoma Cells : Potential Inhibition of Angiogenesis", CLINICAL CANCER RESEARCH, vol. 2, no. 12, December 1996 (1996-12-01), pages 1969 - 1979, XP000979204 *
KUNDU NAMITA ET AL: "Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer.", JOURNAL OF THE NATIONAL CANCER INSTITUTE (BETHESDA), vol. 88, no. 8, 1996, pages 536 - 541, XP000979212, ISSN: 0027-8874 *
RICHTER GUENTHER ET AL: "Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration.", CANCER RESEARCH, vol. 53, no. 18, 1993, pages 4134 - 4137, XP002158948, ISSN: 0008-5472 *
STEARNS M E ET AL: "IL-10 inhibition of human prostate PC-3 ML cell metastases in SCID mice: IL-10 stimulation of TIMP-1 and inhibition of MMP-2/MMP-9 expression.", INVASION & METASTASIS, vol. 17, no. 2, March 1997 (1997-03-01), pages 62 - 74, XP000979206, ISSN: 0251-1789 *
STEARNS MARK ET AL: "Interleukin 10 (IL-10) Inhibition of Primary Human Prostate Cell-induced Angiogenesis : IL-10 Stimulation of Tissue Inhibitor of Metalloproteinase-1 and Inhibition of Matrix Metalloproteinase (MMP)-2/MMP-9 Secretion", CLINICAL CANCER RESEARCH, vol. 5, January 1999 (1999-01-01), pages 189 - 196, XP000979198 *

Also Published As

Publication number Publication date
WO2001005821A2 (fr) 2001-01-25
AU5827000A (en) 2001-02-05

Similar Documents

Publication Publication Date Title
MXPA01006099A (es) Metodos y composiciones para reducir las permeabilidades de zonas subterraneas.
HK1056878A1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1.
HK1047743A1 (en) New use and novel n-azabicyclo-amide derivatives.
ZA991951B (en) Compound and its use.
ZA991975B (en) Enzyme inhibitors.
ZA991953B (en) Detection of fermentation-related microorganisms.
WO2001005821A3 (fr) Utilisations de l'il-10 virale
MXPA01011145A (es) Metodo para la conservacion de virus y micoplasma.
EG23373A (en) Process and intermediates.
MXPA01009950A (es) Sistema de manejo de material y metodo para operar el mismo.
PL345667A1 (en) Perforator for weblike materials with means for modifying the interval between consecutive lines of perforations
ZA200205098B (en) Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2-mediated disorders.
ZA200007405B (en) Angiogenesis inhibitors.
MXPA03004614A (es) Material estabilizado de crepado posterior y metodo para producir el mismo.
MXPA03001557A (es) Derivados bifenilo.
HK1053825A1 (en) Hydrazide and alkoxyamide angiogenesis inhibitors.
ZA200003708B (en) Diamond semiconductor and method for the fabrication thereof.
MXPA03004849A (es) Coniosetina y sus derivados, metodo para producirla y su uso.
AU2001242801A1 (en) Input method for characters and the like
AU2001294426A1 (en) Method of treating feed material, and use of the method
MXPA01011741A (es) Maquina trituradora de llantas y metodo para utilizarla.
HK1047605A1 (en) Carbon film and method of forming the same.
ZA200002158B (en) Outfit and process for the construction of several complex industrial installations.
AU2001283336A1 (en) Selective urokinase inhibitors
AU7401700A (en) Method and device for treating water, especially drinking water, and for maintaining the purity thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP